Abera Bioscience develops next-generation nasal vaccines using a modular OMV platform that enables rapid design, cost-effective production and strong mucosal and systemic immunity.
Board member Mats Wahlström has, in consultation with the Board of Directors, decided to transfer his warrants of series TO2025/2026 to members of Abera Bioscience’s
Abera Bioscience today announced that the Company has completed a ferret study during the spring with its intranasal influenza vaccine candidate. The outcome of the
Abera Bioscience AB (“Abera” or the “Company”) today announced that a scientific article has been accepted for publication in the peer-reviewed journal Vaccine. The publication,
Abera Bioscience’s OMV platform enables rapid, modular vaccine design with high flexibility across disease targets. The technology supports efficient, scalable manufacturing and induces both mucosal and systemic immunity, making it suitable for seasonal, bacterial and emerging pathogens.
The pipeline includes a serotype-independent nasal pneumococcal vaccine preparing for Phase 1 and a nasal influenza vaccine progressing through preclinical development. The platform’s adaptability also provides opportunities for future programs within pandemic preparedness and additional infectious disease areas.
Abera’s platform is designed with global health in mind. Our OMV technology enables scalable, cost-effective vaccine production without eggs, using controlled liquid fermentation. Vaccines can be delivered as a simple nasal spray and have potential for powder formulation — reducing the need for needles, cold chain and complex logistics.
This makes our vaccines well suited for both high-income countries and low-resource settings.
Abera is dedicated to the development of novel vaccines to save lives and increase health globally.
